TY - JOUR
T1 - Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5)
AU - Pagel, Julia
AU - Beutel, Karin
AU - Lehmberg, Kai
AU - Koch, Florian
AU - Maul-Pavicic, Andrea
AU - Rohlfs, Anna Katharina
AU - Al-Jefri, Abdullah
AU - Beier, Rita
AU - Ousager, Lilian Bomme
AU - Ehlert, Karoline
AU - Gross-Wieltsch, Ute
AU - Jorch, Norbert
AU - Kremens, Bernhard
AU - Pekrun, Arnulf
AU - Sparber-Sauer, Monika
AU - Mejstrikova, Ester
AU - Wawer, Angela
AU - Ehl, Stephan
AU - Zur Stadt, Udo
AU - Janka, Gritta
N1 - Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2012/6/21
Y1 - 2012/6/21
N2 - Familial hemophagocytic lymphohistiocytosis (FHL) is a genetically determined hyperinflammatory syndrome caused by uncontrolled immune response mediated by T-lymphocytes, natural killer (NK) cells, and macrophages. STXBP2 mutations have recently been associated with FHL5. To better characterize the genetic and clinical spectrum of FHL5, we analyzed a cohort of 185 patients with suspected FHL for mutations in STXBP2. We detected biallelic mutations in 37 patients from 28 families of various ethnic origins. Missense mutations and mutations affecting 1 of the exon 15 splice sites were the predominant changes detectable in this cohort. Patients with exon 15 splice-site mutations (n = 13) developed clinical manifestations significantly later than patients with other mutations (median age, 4.1 year vs 2 months) and showed less severe impairment of degranulation and cytotoxic function of NK cells and CTLs. Patients with FHL5 showed several atypical features, including sensorineural hearing deficit, abnormal bleeding, and, most frequently, severe diarrhea that was only present in early-onset disease. In conclusion, we report the largest cohort of patients with FHL5 so far, describe an extended disease spectrum, and demonstrate for the first time a clear genotype-phenotype correlation.
AB - Familial hemophagocytic lymphohistiocytosis (FHL) is a genetically determined hyperinflammatory syndrome caused by uncontrolled immune response mediated by T-lymphocytes, natural killer (NK) cells, and macrophages. STXBP2 mutations have recently been associated with FHL5. To better characterize the genetic and clinical spectrum of FHL5, we analyzed a cohort of 185 patients with suspected FHL for mutations in STXBP2. We detected biallelic mutations in 37 patients from 28 families of various ethnic origins. Missense mutations and mutations affecting 1 of the exon 15 splice sites were the predominant changes detectable in this cohort. Patients with exon 15 splice-site mutations (n = 13) developed clinical manifestations significantly later than patients with other mutations (median age, 4.1 year vs 2 months) and showed less severe impairment of degranulation and cytotoxic function of NK cells and CTLs. Patients with FHL5 showed several atypical features, including sensorineural hearing deficit, abnormal bleeding, and, most frequently, severe diarrhea that was only present in early-onset disease. In conclusion, we report the largest cohort of patients with FHL5 so far, describe an extended disease spectrum, and demonstrate for the first time a clear genotype-phenotype correlation.
UR - http://www.scopus.com/inward/record.url?scp=84862749911&partnerID=8YFLogxK
U2 - 10.1182/blood-2011-12-398958
DO - 10.1182/blood-2011-12-398958
M3 - Journal articles
C2 - 22451424
AN - SCOPUS:84862749911
SN - 0006-4971
VL - 119
SP - 6016
EP - 6024
JO - Blood
JF - Blood
IS - 25
ER -